Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.

CONCLUSIONS: It was demonstrated that the use of sacubitril/valsartan in outpatients with HFrEF is safe and is associated with a significant clinical improvement.
PMID: 29192956 [PubMed - indexed for MEDLINE]

Source: Kardiologia Polska - December 12, 2018 Category: Cardiology Authors: Kałużna-Oleksy M, Kolasa J, Migaj J, Pawlak A, Lelonek M, Nessler J, Straburzyńska-Migaj E Tags: Kardiol Pol Source Type: research